Riskpilot← Back to searchSign inGet full accessROSE PHARMA A/S
A/SDissolvedCVR 27174965Universitetsparken 7Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik · NACE 721900Est. 2003— employees
Revenue 2016
DKK -35K
-79% vs 2015
EBITDA margin
100.0%
+79% vs 2015
Equity ratio
69.8%
Financial strength
Net profit 2016
DKK -52K
+72% vs 2015
| Revenue | DKK -35K | -79% |
| EBITDA | DKK -35K | +79% |
| Net profit | DKK -52K | +72% |
| Total assets | DKK 1,4M | +0% |
| Equity | DKK 979K | -5% |
| Employees | — | — |
Legal name
ROSE PHARMA A/S
CVR number
27174965
Legal form
Aktieselskab
NACE code
721900 · Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Founded
12. maj 2003
Share capital
DKK 1.335.204
Employees
—
VAT registered
No
Audit selected
No
Last report
2016-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Universitetsparken 7
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 |
|---|---|---|---|---|---|
| Revenue | -335 | -130 | 263 | -171 | -35 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -335 | -130 | 263 | -171 | -35 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -335 | -130 | 263 | -171 | -35 |
| Net financials | 0 | -4 | -13 | -16 | -17 |
| Profit before tax | -335 | -134 | 250 | -187 | -52 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -335 | -134 | 250 | -187 | -52 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 |
|---|---|---|---|---|---|
| Total assets | 1.556 | 1.447 | 1.439 | 1.404 | 1.402 |
| Equity | 1.102 | 968 | 1.218 | 1.031 | 979 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 454 | 479 | 10 | 373 | 0 |
| Total debt | 454 | 479 | 10 | 373 | 0 |
EBITDA margin
-3521800.0%
This company
15.8%
Market median
-22289973% vs market
20122016
Equity ratio
69.8%
This company
38.2%
Market median
+83% vs market
20122016
Return on equity
-5.3%
This company
18.4%
Market median
-129% vs market
20122016
Net profit margin
-5182100.0%
This company
8.1%
Market median
-63976643% vs market
20122016
Asset turnover
-0.03×
This company
1.12×
Market median
-103% vs market
20122016
Debt / equity
0.43×
This company
0.62×
Market median
+31% vs market
20122016
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CL Management | Management | 2003 | — | — |
LA Management | Management | 2004 | — | — |
JO Founder | Founder | 2003 | — | — |
EK Chief Executive Officer | Chief Executive Officer | 2007 | — | — |
CT Management | Management | 2003 | — | — |
LF Chief Executive Officer | Chief Executive Officer | 2006 | — | — |
Si Founder | Founder | 2003 | — | — |
CT Management | Management | 2003 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2007 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2004 | — | — | |
| Board of Directors | 2003 | — | — | |
| Board of Directors | 2003 | — | — | |
| Chairman | 2006 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2012 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 5.0% | 5.0% | 2016 | |
| Individual | 10.0% | 10.0% | 2016 | |
NORDIC BIOTECH K/S | Company | 33.3% | 33.3% | 2016 |
| Individual | 20.0% | 20.0% | 2016 | |
| Individual | 5.0% | 5.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ROSE PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Cora Louise Madsen | Management | 0 companies |
| Lise Abildgaard Ryberg | Management | 0 companies |
| Johan Olav Svensson | Founder | 0 companies |
| Enda Kenny | Chief Executive Officer | 0 companies |
| Claes Tomas Post | Management | 0 companies |
| Lars Folke Henrik Nilsson | Chief Executive Officer | 0 companies |
| Sahltech i Göteborg AB | Founder | 0 companies |
| Claes Tomas | Management | 0 companies |
| Charles Woler | Board of Directors | 0 companies |
| Michael Forer | Chairman | 0 companies |
| Jeremy Laurence Curnock Cook | Board of Directors | 0 companies |
| Olof Gustav Paulus Isaksson | Board of Directors | 0 companies |
| Tamas Bartfai | Board of Directors | 0 companies |
| Thue Walter Schwartz | Board of Directors | 0 companies |
| John-Olov Jansson | Board of Directors | 0 companies |
| Hans Thalsgård Schambye | Chairman | 0 companies |
| Christian Karsten Hansen | Board of Directors | 0 companies |
| Florian Schønharting | Board of Directors | 0 companies |